Recombinant Human CD80 /B7-1 Protein
- Known as:
- Recombinant Human CD80 /B7-1 Protein
- Catalog number:
- cd-753
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Proxinobio
- Gene target:
- Recombinant Human CD80 /B7-1 Protein
Related genes to: Recombinant Human CD80 /B7-1 Protein
- Gene:
- CD80 NIH gene
- Name:
- CD80 molecule
- Previous symbol:
- CD28LG, CD28LG1
- Synonyms:
- B7.1, B7-1
- Chromosome:
- 3q13.33
- Locus Type:
- gene with protein product
- Date approved:
- 1993-12-14
- Date modifiied:
- 2016-10-05
Related products to: Recombinant Human CD80 /B7-1 Protein
Related articles to: Recombinant Human CD80 /B7-1 Protein
- Intravesical Bacillus Calmette-Guérin (BCG) immunotherapy remains one of the most effective treatments for non-muscle invasive bladder cancer (NMIBC). However, a substantial proportion of patients fail to respond, and the precise mechanisms underlying BCG's therapeutic effects remain incompletely understood. While extracellular vesicles (EVs) can modulate a range of biological processes, their relevance in this context is also poorly understood. - Source: PubMed
Publication date: 2026/04/13
Ortiz-Bonilla Carlos JMolony Ryan DMiyamoto HiroshiMessing EdwardLee Yi-Fen - Trichinellosis is a globally significant zoonotic parasitic disease for which effective preventive strategies remain elusive. Our previous studies identified -Hsp70 as a promising vaccine candidate antigen against , although its precise mechanism of immune protection is not fully understood. Macrophages (Mφ) play pivotal roles in anti-helminth immunity and undergo dynamic M1/M2 polarization shifts during different stages of infection. - Source: PubMed
Publication date: 2026/04/13
Sun QingHuang JingjingGu YuanLiu ShaCheng YuliZhu Xinping - NRF2 modulates tumor immune microenvironment in several cancers. NRF2 is activated in about 50% of high-grade serous ovarian cancer (HGSOC), the most aggressive type of ovarian cancer. Through analyzing data from scRNA-seq (n = 7), bulk RNA-seq (n = 365), and tumor microarray (TMA) of human HGSOC (n = 240) samples, we demonstrated that NRF2 expression correlated with tumor immune microenvironment in HGSOC. Functional pathway enrichment analysis and transcription factors (TFs) prediction showed the functional relevance of NRF2 expression in shaping the immune phenotype of HGSOC. Pathways such as hedgehog and ROS signaling, and TFs including EGR1, ESRRA, SMAD proteins, and SP-family proteins, are implicated in the immune suppressive microenvironment of NRF2 tumors. Immune differentiation analysis showed patients with NRF2 tumors enriched with CD68 have lower survival (p = 0.038) than those with CD68 tumors, whereas NRF2 tumors enriched with immune-activated markers such as CD3E and CD80 exhibit a better prognosis. This study is the first that shows classification of HGSOC based on NRF2 levels, highlights new biomarkers, and suggests IHC-labeling and genomic evaluation of NRF2 and immune markers for better prognosis. - Source: PubMed
Publication date: 2026/04/28
Hamad Samera HKatz ChelseaToma HelenMurakami KosukeBendjilali NasrineZhu GordShojaei HadiFang LanlanLeung SamuelKoebel MartinKaraduman HuseyinAbinader OliverMitra RamkrishnaKrill LaurenChu ChristinaWarshal David PWang Yemin - Graphene quantum dots (GQDs) belong to the carbon quantum dot family, with low toxicity, high biocompatibility, and excellent colloidal stability. Mesoporous silica nanoparticles (MSNs) are recognized as effective drug delivery systems due to their high drug-loading capacity, while glucosamine sulfate (GS) exhibits immunemodulatory properties. In this study, to maximize the immune effect of GS, a graphene quantum dot-coated mesoporous silica loaded with glucosamine sulfate (MSN-G-Q) is synthesized, and its immunoactivation effects are evaluated in vitro and in vivo. In vitro, MSN-G-Q enhances macrophage uptake activity, stimulates nitric oxide (NO) production, and upregulates CD80 and CD86 expression. In vivo, MSN-G-Q/OVA increases immune organ index, facilitates dendritic cell (DC) maturation, promotes T lymphocyte proliferation and differentiation, elevates antigen-specific IgG antibodies and cytokines, including IFN-γ, IL-4, and IL-1β, and prolongs ovalbumin (OVA) residence in immune organs and lymph nodes. The results show that MSN-G-Q/OVA is a promising immunostimulatory antigen delivery system. - Source: PubMed
Publication date: 2026/04/28
Wang QiranYang ShuyaoWang YaoLi HangyuLi YuanzuoDu XihuiYang QianWang FengyuanFeng Haibo - Cytomegalovirus (CMV) remains a major infectious complication after solid-organ transplantation, driven by immunosuppressive therapies that alter CMV-specific cell-mediated immunity. Antithymocyte globulin induces profound and prolonged T-cell depletion, transiently impairing CMV-specific cell-mediated immunity and increasing CMV risk in seropositive recipients. Calcineurin inhibitors suppress cytokine production, notably IL-2 and IFN-γ, without significantly impairing cytotoxic function, while mycophenolate mofetil limits lymphocyte proliferation but preserves effector capacity. In contrast, mTOR inhibitors exert dual antiviral and immunomodulatory effects by directly inhibiting CMV replication and enhancing CMV-specific T-cell memory formation. Belatacept, through CD28-CD80/CD86 blockade, may predispose to late, severe, or relapsing CMV disease, particularly in elderly or D/R recipients. Corticosteroids broadly inhibit NK cell cytotoxicity and CMV-specific T-cell responses, but clinical data on steroid withdrawal remain inconsistent. Overall, CMV risk is determined less by a single drug than by the cumulative depth of immunosuppression. Integrating immune monitoring tools, such as CMV-specific T-cell assays, could enable tailored immunosuppressive regimens balancing antiviral protection with graft survival. - Source: PubMed
Publication date: 2026/04/09
Bellier Lucas MiloKaminski HannahMerville PierreCouzi Lionel